Clinical Trials Logo

Pneumonitis, Interstitial clinical trials

View clinical trials related to Pneumonitis, Interstitial.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02251964 Completed - Clinical trials for Lung Diseases, Interstitial

Rituximab in Interstitial Pneumonitis

RITUX-IP
Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This project will address rare immune mediated inflammatory diseases (IMIDs) involving the lungs, i.e. interstitial pneumonitis (IP). The main objective of this study is to assess the effects of rituximab (RTX) as a rescue therapy for progressive IMID-IP patients. The primary study parameter is pulmonary function. The secondary objectives are to explore the application of imaging with radiolabeled RTX as early predictor for efficacy of RTX, to study the effects of RTX treatment on quality of life, and to further elucidate the pathophysiology of IMID-IP by analyzing biochemical markers.